FREMONT, Calif., Aug. 5, 2015 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused
on gastrointestinal and cardio-renal diseases, today announced that
it will report second quarter 2015 financial results on
Wednesday, August 12, 2015. Following
the announcement, the Ardelyx management team will host a live
conference call and webcast at 8:00am
Eastern Time to review the Company's financial results and
provide a business update.
![Ardelyx logo Ardelyx logo](http://photos.prnewswire.com/prnvar/20140619/119451)
The live webcast can be accessed by visiting the investor
section of Ardelyx's website at ir.ardelyx.com. Please connect to
the Company's website at least 15 minutes prior to the live webcast
to ensure adequate time for any software download that may be
needed to access the webcast. Alternatively, please call
1-855-296-9612 (US) or 920-663-6277 (International) to listen to
the conference call. The conference ID number for the live call
will be 97651804. Following the webcast, an archived version of the
call will be available on the Company's website until August 26, 2015.
About Ardelyx
Ardelyx is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative, minimally-systemic, small molecule therapeutics that
work exclusively in the gastrointestinal tract to treat
gastrointestinal and cardio-renal diseases. Ardelyx has
developed a proprietary drug discovery and design platform enabling
it, in a rapid and cost-efficient manner, to discover and design
novel drug candidates. Utilizing this platform, the Company has
discovered and designed tenapanor, which it is evaluating for the
treatment of IBS-C and hyperphosphatemia in chronic kidney disease
patients on dialysis. In addition to
tenapanor, Ardelyx is developing RDX022, a non-absorbed
polymer for the treatment of hyperkalemia, or high potassium, in
kidney and heart disease patients, and has discovered small
molecule NaP2b inhibitors for the treatment of hyperphosphatemia in
CKD patients on dialysis, a program licensed to
Sanofi. Ardelyx is also independently advancing
several research programs focused in gastrointestinal and
cardio-renal diseases. Ardelyx is located
in Fremont, California. For
more information, please visit Ardelyx's website
at www.ardelyx.com.
Logo -
http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-to-report-second-quarter-2015-financial-results-on-august-12-2015-300124355.html
SOURCE Ardelyx